Plus Therapeutics adds Kyle Guse to its Board of Directors

HOUSTON - Plus Therapeutics, Inc. (NASDAQ:PSTV), a clinical-stage pharmaceutical company specializing in central nervous system (CNS) cancer treatments, announced the appointment of Kyle Guse as a new member of its Board of Directors. Guse will also serve as the chair of the Audit Committee and a member of the Compensation Committee. According to InvestingPro data, the company, currently valued at $13.4 million in market capitalization, faces financial challenges with weak gross profit margins and rapid cash burn, though its stock has shown significant momentum with a 17% return over the past week.

Kyle Guse brings over 30 years of experience in the financial and legal sectors, having held significant roles in innovative companies. His previous positions include serving as CFO, General Counsel, and Secretary at Atossa Therapeutics, Inc., and currently as Chief Legal Officer at DDC Enterprise Ltd. His expertise extends to corporate law practice at top international firms and his foundational experience as a Certified Public Accountant with a major accounting firm. His appointment comes at a crucial time, as InvestingPro analysis reveals the company’s current ratio of 0.34 indicates challenges in meeting short-term obligations.

The company’s President and CEO, Marc H. Hedrick, M.D., expressed confidence that Guse’s extensive industry experience would contribute positively to the board’s effectiveness and aid in the execution of Plus Therapeutics’ ambitious business plans.

Guse’s appointment comes as Plus Therapeutics continues to focus on developing its pipeline of radiotherapeutics. The company is working on advancing product candidates, with leading programs targeting leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). These efforts are supported by a strategic supply chain intended to facilitate development, manufacturing, and potential future commercialization.

The company’s press release also included statements by Guse, who expressed enthusiasm for the opportunities at Plus Therapeutics in both therapeutics and diagnostics markets. He highlighted the potential of the company’s products, including REYOBIQ™ (rhenium Re186 obisbemeda) and CNSide, to impact the market and benefit stockholders, practitioners, and patients. Recent financial data from InvestingPro shows revenue growth of 18.5% in the last twelve months, though analysts anticipate a sales decline in the current year. For deeper insights into Plus Therapeutics’ financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

This announcement is based on a press release statement from Plus Therapeutics, Inc. The company cautions that forward-looking statements within the press release are subject to risks and uncertainties, including the development stages of its product candidates, clinical trial outcomes, financial resources, and market conditions. Plus Therapeutics has made these cautionary remarks to provide context for the forward-looking statements and does not assume responsibility for updating them after the date of the press release.

In other recent news, Plus Therapeutics has reported its financial results for 2024, revealing grant revenues of $5.8 million, which fell short of the consensus estimate of $6.4 million. The company also disclosed a net loss of $1.95 per share, aligning closely with the projected $1.94 per share loss. H.C. Wainwright has adjusted its price target for Plus Therapeutics to $5.50 from the previous $8.00, while maintaining a Buy rating on the stock. The firm forecasts total grant and product revenues of $11.4 million for 2025, with a projected net loss of $0.34 per share.

Additionally, Plus Therapeutics has announced progress in its clinical-stage programs, particularly with its lead compound REYOBIQ™ for CNS cancers. The Phase 1 ReSPECT-LM trial showed promising results, with a 75% Clinical Benefit Rate and no dose-limiting toxicity observed in the initial cohorts. The company is advancing its Ryobiq drug with FDA acceptance and orphan designation, and plans are underway for a limited launch of the C-Inside diagnostic test in 2025.

Plus Therapeutics also completed a $15 million private placement in March 2025, boosting its cash position to $18.6 million. Analysts at H.C. Wainwright believe these funds will support the company’s operations through the first quarter of 2026. The company is also preparing for a multiple dose escalation trial for Ryobiq and expects to complete enrollment for the RESPECT GBM Phase II trial by the end of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.